Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals Q1 2023 Earnings Report

PMV Pharmaceuticals logo
$1.00 -0.04 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$0.95 -0.05 (-4.90%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Wednesday, May 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

PMV Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals (NASDAQ:PMVP) Shares Down 3.7% - Time to Sell?
PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
PMV Pharmaceuticals sees cash runway to end of 2026
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat